<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EPTIFIBATIDE</span><br/>(ep-ti-fib'a-tide)<br/><span class="topboxtradename">Integrilin<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antithrombotic agent</span>; <span class="classification">antiplatelet antibody</span>; <span class="classification">glycoprotein iib/iiia inhibitor</span><br/><b>Prototype: </b>Abciximab<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.75 mg/mL, 2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Binds to the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor sites of platelets.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits platelet aggregation by preventing fibrinogen, von Willebrand's factor, and other molecules from adhering to GPIIb/IIIa
         receptor sites on platelets.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of acute coronary syndromes (unstable angina, non-Q-wave MI) and patients undergoing percutaneous coronary interventions
         (PCIs).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to eptifibatide; active bleeding; GI or GU bleeding within 6 weeks; thrombocytopenia; recent major surgery
         or trauma; intracranial neoplasm, intracranial bleeding within 6 mo; concurrent administration of another GPIIb/IIIa receptor
         inhibitor (e.g., abciximab); renal dialysis; severe hypertension (systolic blood pressure &gt;200 mm Hg or diastolic blood pressure
         &gt;110 mm Hg), aneurysm.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to related compounds (e.g., abciximab, tirofiban, lamifiban); concurrent administration of other anticoagulants;
         pregnancy (category B), lactation. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Coronary Syndromes (ACS)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 180 mcg/kg initial bolus followed by 2 mcg/kg/min until hospital discharge or up to 72 h<br/><br/><span class="indicationtitle">PCI in Patients with ACS</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 180 mcg/kg initial bolus followed by 0.5 mcg/kg/min for 2024 h after end of procedure<br/><br/><span class="indicationtitle">PCI in Patients without ACS</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 135 mcg/kg initial bolus followed by 0.5 mcg/kg/min for 2024 h after end of procedure<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Review contraindications to administration prior to giving this drug.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give bolus doses IV push over 12.  <span class="methodtype">Continuous:</span> Start continuous infusion immediately following bolus dose. Give undiluted directly from the 100-mL vial (at a rate based
                  on patient's weight) using a vented infusion set. May be given in the same IV line with NS or D5/NS (either solution may contain
                  up to 60 mEq KCl).  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials at 2°8° C (36°46° F) and protect from light. Discard any unused portion
            in opened vial.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Intracranial bleed (rare). <span class="typehead"> GI:</span>  GI bleeding. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Bleeding</span> (major bleeding 4.411%), anemia, thrombocytopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">oral anticoagulants</span>, <span class="classification">nsaids</span>, <b>dipyridamole,</b>
<b>ticlopidine,</b>
<b>dextran</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 68 h after stopping infusion. <span class="typehead">Distribution:</span> 25% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized. <span class="typehead">Elimination:</span> 50% excreted in urine. <span class="typehead">Half-Life:</span> 2.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Prior to infusion determine PT/aPTT &amp; INR, ACT for those undergoing percutaneous coronary intervention (PCI); Hct
            or Hgb; platelet count; and serum creatinine.
         </li>
<li>Lab tests: Monitor aPTT &amp; INR (target aPPT, 5070 s); during PCI (target ACT, 300350 s).</li>
<li>Minimize all vascular and other trauma during treatment. When obtaining IV access, avoid using a noncompressible site such
            as the subclavian vein.
         </li>
<li>Monitor carefully for and immediately report S&amp;S of bleeding (e.g., femoral artery access site bleeding, intracerebral hemorrhage,
            GI bleeding).
         </li>
<li>Immediately stop infusion of eptifibatide and heparin if bleeding at the arterial access site cannot be controlled by pressure.</li>
<li>Achieve hemostasis at the arterial access site by standard compression for a minimum of 4 h prior to hospital discharge following
            discontinuation of eptifibatide and heparin.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>